News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LFB S.A. Initiates Global Phase 3 Clinical Trial Of New Coagulation Factor Viia (Recombinant) In Patients With Hemophilia A And B


3/3/2014 9:17:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FRAMINGHAM, Mass.--(BUSINESS WIRE)--LFB SA, through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
LFB S.A.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES